40 results about "Streptococcus pyogenes" patented technology

The invention belongs to the technical field of microorganisms, and relates to a strain of herbaspirillum as well as a fermentation method and application thereof. The invention provides a strain of brassica juncea, the brassica juncea is brassica juncea YLHb25.7, the brassica juncea is named as Herbaspiril huttiense, the brassica juncea is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.35297. The invention also provides a preparation method of the brassica juncea. The herbispirillum sp. YLHb25.7 disclosed by the invention has the capabilities of producing ACC deaminase, producing IAA and fixing nitrogen, and has good drought resistance and saline-alkaline tolerance. The herbaspirillum sp. YLHb25.7 and the fermentation product thereof can promote the growth of wheat and corn, can be used as a microbial agent or bacterial fertilizer, and can be applied to the agricultural market.

The invention provides a primer group for identifying multiple genes of ten bacteria related to lower respiratory tract infection and application of the primer group, and belongs to the technical field of gene detection, the sequence of the primer group is shown as SEQ ID NO.1-20, the primer group designs specific primers for ten bacteria such as pseudomonas aeruginosa and streptococcus pyogenes, and the specific primers of ten genes of a 5'end primer are labeled by FAM fluorescence. 10 target gene loci and 2 internal reference loci can be detected in one PCR system, the traditional PCR deviation is overcome, and gene expression is accurately quantified. The reagent and the kit developed on the basis have the advantages of simplicity and convenience in operation, low cost, high accuracy and the like. When the kit is used, DNA of a sample is extracted for multiple PCR, and pathogen load is determined through electrophoresis and software analysis. Experiments prove that the method has strong specificity and high sensitivity to 10 bacteria, and has important application value in LRTI bacterial identification.

Compositions comprising 5. salivarius strain SALI-10 and / or salivarius 10 peptide are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.

The invention provides a strain of high-temperature-resistant and inflammation-relieving Witzia ciliaris and an application thereof, the high-temperature-resistant and inflammation-relieving Witzia ciliaris is Witzia ciliaris CN985 and is preserved in the China Center for Type Culture Collection (CCTCC), the preservation date is April 7, 2024, and the preservation number is CCTCC NO: M 2024641. The invention further provides a preparation method of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain for preventing and treating inflammation of the high-temperature-resistant and inflammation-relieving Witzia ciliaris strain. The invention provides a brand new strain of Witzia ciliaris CN985, which is resistant to high temperature, has better acid resistance and bile resistance, and has no hemolysis risk when being applied to a human body. The Witzia coagulans CN985 has excellent antibacterial performance, and especially can significantly inhibit streptococcus pyogenes, salmonella enteritidis and / or group B streptococcus; besides, experimental results show that the Witzia ciliaris CN985 can relieve enteritis, improve the immunity of the organism and relieve pharyngitis, and especially when the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 are combined for use, the Witzia ciliaris CN985 and the phytobacterium plantarum CE18 have a synergistic interaction effect, so that the relieving effect on enteritis can be remarkably improved.

The present invention provides a Lactiplantibacillus plantarum strain capable of resisting Streptococcus pneumoniae infection in the respiratory tract, with a deposit number of CCTCC NO: M2022359. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has a strong adhesion effect on nasal epithelial cells and can colonize in the nasal cavity; and can significantly inhibit the adhesion effect of Streptococcus pneumoniae, the main pathogenic microorganism of sinusitis, on nasal epithelial cells; it also has an inhibitory effect on the growth of most other pathogenic microorganisms of sinusitis, including β-hemolytic streptococcus, Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus, etc. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has no toxic effect on the body and has good safety. It can be added to drugs for preventing respiratory diseases or improving respiratory symptoms caused by bacterial infections, and has broad application prospects.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The application discloses a super-sensitive detection composition of aquatic product pathogenic bacteria and an application and a detection method thereof, and belongs to the technical field of biotechnology.The composition comprises an amplification primer with a sequence shown as SEQ ID No.1-2, a hairpin probe H1 with a fluorescent group and a quenching group modified on a nucleotide sequence shown as SEQ ID No.3, and a hairpin probe H2 with a sequence shown as SEQ ID No.4.Compared with conventional detection technologies such as a bacterial culture method, an instrument analysis method, a molecular biology method and an immunology method, the application provides a set of amplification primers and hairpin probes based on HCR, has higher specificity when detecting escherichia coli of aquatic products, and can avoid the influence of staphylococcus aureus, streptococcus pyogenes, pseudomonas aeruginosa and salmonella; meanwhile, the application has better sensitivity, and the detection limit can reach 0.4 CFU / mL; in addition, compared with other hairpin probes, the application can avoid false positives and improve reaction efficiency.

A base editing system for achieving A-to-C and / or A-to-T base mutations and a use thereof are provided. A base editor is constructed by means of fusing 3-methyladenine DNA glycosylase with adenosine deaminase and Cas9 nuclease with impaired catalytic activity, which achieves adenine-based transversion for the first time. It is found through experimental comparison that AXBE, which is constructed by means of fusing mouse-derived 3-methyladenine DNA glycosylase with adenosine deaminase TadA-8e derived from E. coli and Cas9 nickase with impaired catalytic activity derived from Streptococcus pyogenes, has the best effect of catalyzing the transversion of adenine. The use of the base editing system in the gene therapy, cell therapy, human disease model production, and crop genetic breeding, etc. is promoted.

The present invention relates to the technical field of rapid molecular detection, and provides a detection kit and a detection method for Streptococcus pyogenes. The detection method provided by the present invention comprises using a multiple cross-displacement amplification method, using MCDA primers to perform an amplification reaction on the DNA of a sample to be tested, and preparing an amplification product; a restriction endonuclease recognizes and cuts the restriction endonuclease recognition sequence, releases a fluorescent quenching group, and emits a fluorescent signal; and the fluorescent signal is detected to detect the Streptococcus pyogenes. The detection method provided by the present invention is rapid, highly sensitive, and highly specific, can reduce dependence on precision instruments, is easy to operate, and the results can be read intuitively, is not limited by the site, and can improve the early detection rate of GAS.

The invention discloses a mixed extract of neem fruit and neem bark, and a preparation method and application thereof, belonging to the technical field of extracts. The preparation method comprises the following steps: S01, pretreatment: crushing and sieving neem fruit and neem bark with a mass ratio of 1: (2-4.5), and mixing to obtain a composite powder; S02, extraction: adding a non-polar solvent to the composite powder, soaking, extracting, and filtering; after the filter residue evaporates the solvent, adding a polar solvent to the filter residue, extracting, filtering, and concentrating to obtain a crude extract; S03, purification: purifying the crude extract with a macroporous adsorption resin, concentrating, and drying. The raw materials for preparing the plant-derived antibacterial agent of the invention are derived from neem fruit and neem bark, which cooperate with each other and have a synergistic effect, and show good antibacterial properties against Escherichia coli, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Salmonella typhimurium, Klebsiella pneumoniae and other bacteria.

The present application relates to a Pichia pastoris indirect surface display system based on SpyC / T, construction and application thereof, and relates to the technical field of bioengineering. The Pichia pastoris indirect surface display system uses SED1 protein from Saccharomyces cerevisiae as an anchor protein, and fixes SpyC from Streptococcus pyogenes on the anchor protein on the surface of Pichia pastoris cells. The present application uses SED1 protein from Saccharomyces cerevisiae as an anchor protein, displays SpyC on the surface of Pichia pastoris, fixes various target proteins containing SpyTag on the cell surface through strong interaction of SpyC / T, so as to indirectly display the target proteins containing SpyTag on the surface of Pichia pastoris, exert the function of the target proteins containing SpyTag, and improve the stability of the target proteins.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Streptococcus pyogenes Cas9 (SpCas9) variants with relaxed PAM requirements capable of high-resolution editing for various applications, and methods of use thereof.

Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.

The present invention relates to methods of treating diseases in a subject in need thereof, including proliferative diseases such as cancer, especially solid tumors, as well as other diseases involving invasive cells or entities such as viruses, bacteria, fungi, and parasites, using IgG antibodies, including anti-tumor IgG antibodies, and a protease from Streptococcus pyogenes.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Described herein are compositions, methods, and kits for detecting wound pathogens. One embodiment described herein is primer pairs and probes for individual, simultaneous, or sequential multiplex polymerase chain reaction (PCR) based assays for the detection of Acinetobacter baumannii, Bacteroides fragilis, Clostridium perfringens, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Klebsiella Oxytoca, Klebsiella aerogenes, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus pyogenes, Streptococcus anginosus, Staphylococcus lugdunensis, Providencia stuartii, Stenotrophomonas maltophilia, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Citrobacter braakii, Peptoniphilus asaccharolyticus, Peptoniphilus harei, Peptoniphilus ivorii, Peptostreptococcus anaerobius, Finegoldia magna, Clostridium septicum, Paeniclostridium sordellii (Clostridium sordellii), Clostridium novyi A, B, Clostridium histolyticum, Staphylococcus epidermidis, Staphylococcus haemolyticus, Corynebacterium striatum, Candida albicans, Candida auris, Candida glabrata, Candida krusei, Candida parapsilosis, or Candida tropicalis.

The present disclosure relates to methods of treating triple negative breast cancer or non-muscle invasive bladder cancer in a subject comprising administering to the subject a composition comprising non-viable cells of Streptococcus pyogenes and an immune checkpoint inhibitor.

The present disclosure relates to a method for purifying an immunoglobulin degrading enzyme (IdeS) from Streptococcus pyogenes, preferably to a method for removing IdeS charge variants and IdeS obtainable from said method.

The present disclosure discloses a SpCas9 variant. The SpCas9 variant is characterized by the ability to recognize a PAM sequence different from that of a wild-type SpCas9 protein.

This invention relates to the field of microbial technology, and provides a composite microbial suspension comprising a *Streptococcus pyogenes* R3 suspension and a *Cyclocarya pallida* N4 suspension in a volume ratio of 1-2:1-2; the *Streptococcus pyogenes* R3 classification name is... Herbaspirillum sp. R3 was deposited on September 20, 2023, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M 20231757; the taxonomic name of Chlorella N4 is... Chryseobacterium endophyticum N4 was deposited on March 31, 2025, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M 2025633. The aforementioned composite microbial suspension promotes nitrogen fixation and nitrogen conversion.

Engineered Streptococcus canis Cas9 (ScCas9) variants include an ScCas9 protein with its PID being the PID amino acid composition of Streptococcus pyogenes Cas9 (SpCas9-NG, an ScCas9 protein having a threonine-to-lysine substitution mutation at position 1227 in its amino acid sequence (Sc+), and an ScCas9 protein having a threonine-to-lysine substitution mutation at position 1227 and a substitution of residues ADKKLRKRSGKLATE [SEQ ID No. 4] in position 365-379 in the ScCas9 open reading frame (Sc++). Also included are CRISPR-associated DNA endonucleases with a PAM specificity of 5′-NG-3′ or 5′-NNG-3′ and a method of altering expression of a gene product by utilizing the engineered ScCas9 variants.

This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR / Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR / Cas endonuclease system, wherein the CRISPR / Cas endonuclease system displays increased on-target editing activity relative to a wild-type CRISPR / Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR / Cas endonuclease systems having mutant Cas9 proteins that display increased on-target editing activity relative to a wild-type CRISPR / Cas endonuclease system.

The present disclosure relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present disclosure provides for compositions that may induce modifications in target endogenous nucleic acid sequences in nucleuses of eukaryotic cells. The composition may comprise a single-chain guide RNA (sgRNA) and a Streptococcus pyogenes Cas9 protein. In some embodiments, the sgRNA and the Cas9 protein may be present in a molar ratio ranging from 29:14.0 to 29:1.4.

Applications of a Streptococcus Cas9 ortholog from Streptococcus macacae (Smac Cas9), possessing minimal adenine-rich PAM specificity, include an isolated Streptococcus macacae Cas9 protein or transgene expression thereof, a CRISPR-associated DNA endonuclease with PAM interacting domain amino acid sequences that are at least 80% identical to that of the isolated Streptococcus macacae Cas9 protein, and an isolated, engineered Streptococcus pyogenes Cas9 (Spy Cas9) protein with a PID as either the PID amino acid composition of the isolated Streptococcus macacae Cas9 (Smac Cas9) protein or of a CRISPR-associated DNA endonuclease with PID amino acid sequences that are at least 80% identical to that of the isolated Streptococcus macacae Cas9 protein. A method for altering expression of at least one gene product employs Streptococcus macacae Cas9 endonucleases in complex with guide RNA, for specific recognition and activity on a DNA target immediately upstream of either an “NAA” or “NA” or “NAAN” PAM sequence.

The invention provides a yin-nourishing and lung-moistening fermentation composition and a preparation method thereof. The yin-nourishing and lung-moistening composition with efficient bacteriostatic activity is produced on the basis of a stepped fermentation process. The method comprises the following steps: firstly, carrying out first-stage fermentation on radix ophiopogonis and codonopsis pilosula by utilizing plant lactobacillus MG360; after fermenting for 12 hours, supplementing the extracts of the pears, the liquorice and the loquats and the casei paracasei ID001, and carrying out second-stage fermentation. According to the unique stepped fed-batch fermentation process, the antibacterial effect of the plantaricin EF on pneumonia-related pathogenic bacteria, including streptococcus pneumoniae, beta hemolytic streptococcus, pyogenic streptococcus, escherichia coli, staphylococcus aureus and the like, can be remarkably improved. Meanwhile, the expression of related genes pln-E and pln-F is up-regulated. Animal experiments prove that the composition has excellent effects of nourishing yin, moistening the lung, clearing away the lung-heat and resisting inflammation. The traditional medicinal and edible raw materials are combined with the modern microbial fermentation technology, and a new strategy is provided for developing novel functional products capable of nourishing yin, moistening the lung and resisting infection.

Engineered versions of Streptococcus pyogenes Cas9 (SpCas9) and SpCas9 variants that have improved on-target editing capabilities, and methods of use thereof.

The invention relates to a primer, a probe and a detection method for rapidly detecting bone and joint infection pathogens. Comprising at least three groups of primers and probes in primers and probes respectively aiming at staphylococcus aureus, acinetobacter baumannii, staphylococcus epidermidis, staphylococcus hemolyticus, pseudomonas aeruginosa, enterobacter cloacae, escherichia coli, methicillin-resistant staphylococcus aureus and streptococcus pyogenes. According to the invention, the defects of small flux and few types of detectable pathogens in the existing bone and joint infection detection method are overcome, and 9 groups of specially designed primers and probes respectively aim at 9 bone and joint infection pathogens covering 90% or more of bone and joint infection cases; the kit has the advantages that the flux is large (at least three bone and joint infection pathogens can be detected at a time), multiple types of pathogens can be detected, and the specificity and the sensitivity are good.

The invention discloses a recombinant uridine diphosphate glucose dehydrogenase mutant and a preparation method thereof, and relates to the technical field of biology, the mutant is derived from pyogenic streptococcus and is obtained through site-specific mutagenesis (mutation site L102V-H129K-I270G), double tags of His-tag and SUMO-tag are fused at the N terminal, the corresponding protein sequence is SEQIDNO.1, and the coding gene sequence is SEQIDNO.2. Compared with a recombinant wild type UGD, the mutant has the advantages that the mutagenesis efficiency is high, and the mutagenesis efficiency is high. The performance of the mutant is remarkably improved, the catalytic activity reaches 1.8 times of that of a wild type, the residual activity is 69.4% after the mutant is stored at room temperature for 5 days, the soluble expression quantity is improved by 5 times, UDPG can be efficiently promoted to be oxidized to generate UDPGA, the commercial production cost of UDPGA is effectively reduced, and the mutant has a wide application prospect. The invention is suitable for the fields of scientific research reagents, biological medicines, cosmetics and the like.

Compositions comprising a pre-SrnA1 peptide, an SrnA1 peptide, a pre-SrnA2 peptide, an SrnA2 peptide, a pre-SrnA4 peptide, a SrnA4, and other peptides and post-translationally modified versions thereof are taught. Also taught are methods of treating bacterial infections comprising administering a pharmaceutically acceptable amount of the composition to the patient with a bacterial infection caused by a pathogen from, for example, multi-drug resistant (MDR) Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus dysagalactiae, vancomycin-resistant Enterococcus faecium, Porphyromonas gingivalis, Tannerella forsythia, and MDR Enterococcus faecalis.